Pasireotide

Indications & Dose:

Cushing's disease when surgery has failed or is inappropriate

BY SUBCUTANEOUS INJECTION

Adult: Initially 600 micrograms twice daily for 2 months then increased if necessary to 900 micrograms twice daily consider discontinuation if no response within 2 months for dose adjustment due to side effects-consult product literature.

Contraindications:

-

Side Effects:

Adrenal insufficiency . alopecia . anaemia . arthralgia . bradycardia . decreased appetite . fatigue . headache . hyperglycaemia . hypotension . myalgia . pruritus . QT-interval prolongation

PREGNANCY Avoid

BREAST FEEDING Avoid

HEPATIC IMPAIRMENT Reduce initial dose to 300 micrograms twice daily (increased if necessary after 2 months to max. 600 micrograms twice daily) in moderate

impairment. Avoid in severe impairment.

MONITORING REQUIREMENTS

Monitor liver function before treatment and after 1, 2, 4, 8, and 12 weeks of treatment.

QT-interval prolongation Monitor ECG and electrolytes in patients susceptible to QT-prolongation before treatment after one week and periodically thereafter.

Diabetes mellitus In diabetic patients assess glycaemic status before treatment weekly for the first 2-3 months of treatment periodically thereafter and 3 months after treatment is complete.

Cautions:

Cardiac disorders (including bradycardia). susceptibility to QT-interval prolongation (including electrolyte disturbances)

Precautions:

-

Interaction:

-

Warnings:

-

Adverse Effects:

-

Lactations:

-

Special Precautions:

-

Counselling:

-

Side Effects Or Adverse Reactions:

-

Patient And Carer Advice:

-